{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T18:58:00Z","timestamp":1775329080590,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T00:00:00Z","timestamp":1590451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T00:00:00Z","timestamp":1590451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Grants-in-Aid for Scientific Research","award":["17K16691"],"award-info":[{"award-number":["17K16691"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Orthop Surg Res"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mirogabalin, which is approved for the treatment of peripheral neuropathic pain in Japan, is a ligand for the \u03b12\u03b4 subunit of voltage-gated calcium channels. Both pregabalin and mirogabalin act as nonselective ligands at the \u03b12\u03b4-1 and \u03b12\u03b4-2 subunits. Mirogabalin has a unique binding profile and long duration of action. Pregabalin has been reported to produce intolerable adverse effects in some patients. This study investigated outcomes associated with mirogabalin administration in patients with peripheral neuropathic pain who ceased treatment with pregabalin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively assessed peripheral neuropathic pain using the neuropathic pain screening questionnaire (NeP score) in 187 patients (58 men, 129 women) who were treated with mirogabalin. All patients had switched from pregabalin to mirogabalin due to lack of efficacy or adverse events. Differences in the treatment course (i.e., numeric rating scale (NRS) scores) were compared using one-way analysis of variance with Bonferroni post hoc tests.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The mean age of the patients was 72.3\u2009years (range, 30\u201394\u2009years), and the mean duration of disease was 37\u2009months (range, 3\u2013252\u2009months). After treatment with mirogabalin for 1\u2009week, NRS scores significantly decreased compared with baseline and continued to decrease over time. After 8\u2009weeks, NRS scores improved by \u2265\u200930% from baseline in 113 patients (69.3%). Twenty-four patients (12.8%) stopped mirogabalin treatment due to adverse events. Somnolence (26.7%), dizziness (12.3%), edema (5.9%), and weight gain (0.5%) were noted as adverse events of mirogabalin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The results of this investigation indicate that mirogabalin is safe and effective for reducing peripheral neuropathic pain.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13018-020-01709-3","type":"journal-article","created":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T03:03:29Z","timestamp":1590462209000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Short-term outcomes of mirogabalin in patients with peripheral neuropathic pain: a retrospective study"],"prefix":"10.1186","volume":"15","author":[{"given":"Tomoko","family":"Tetsunaga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4348-9806","authenticated-orcid":false,"given":"Tomonori","family":"Tetsunaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichiro","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruo","family":"Misawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyuki","family":"Takigawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Yamane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironori","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitaka","family":"Takei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshifumi","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,26]]},"reference":[{"key":"1709_CR1","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1016\/j.pain.2011.06.017","volume":"152","author":"TS Jensen","year":"2011","unstructured":"Jensen TS, Baron R, Haanpaa M, Kalso E, Loeser JD, Rice AS, et al. A new definition of neuropathic pain. Pain. 2011;152:2204\u20135. https:\/\/doi.org\/10.1016\/j.pain.2011.06.017.","journal-title":"Pain."},{"key":"1709_CR2","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2165\/00019053-200927020-00002","volume":"27","author":"AB O'Connor","year":"2009","unstructured":"O'Connor AB. Neuropathic pain: quality-of-life impact, costs and cost effectiveness of therapy. Pharmacoeconomics. 2009;27:95\u2013112. https:\/\/doi.org\/10.2165\/00019053-200927020-00002.","journal-title":"Pharmacoeconomics."},{"key":"1709_CR3","doi-asserted-by":"crossref","unstructured":"Baron R, Binder A. [How neuropathic is sciatica? The mixed pain concept]. Orthopade. 2004;33:568-75. doi: 10.1007\/s00132-004-0645-0 [doi].","DOI":"10.1007\/s00132-004-0645-0"},{"key":"1709_CR4","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1185\/030079906x132488","volume":"22","author":"R Freynhagen","year":"2006","unstructured":"Freynhagen R, Baron R. Gockel U. Tolle TR. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin. 2006;22:1911\u201320. https:\/\/doi.org\/10.1185\/030079906x132488.","journal-title":"Tolle TR. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin."},{"key":"1709_CR5","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1124\/pr.117.014399","volume":"70","author":"SRA Alles","year":"2018","unstructured":"Alles SRA, Smith PA. Etiology and pharmacology of neuropathic pain. Pharmacol Rev. 2018;70:315\u201347. https:\/\/doi.org\/10.1124\/pr.117.014399.","journal-title":"Pharmacol Rev."},{"key":"1709_CR6","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s40122-017-0087-0","volume":"6","author":"G Cruccu","year":"2017","unstructured":"Cruccu G, Truini A. A review of neuropathic pain: from guidelines to clinical practice. Pain Ther. 2017;6:35\u201342. https:\/\/doi.org\/10.1007\/s40122-017-0087-0.","journal-title":"Pain Ther."},{"key":"1709_CR7","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1111\/j.1471-4159.2010.06625.x","volume":"113","author":"N Kumar","year":"2010","unstructured":"Kumar N, Laferriere A, Yu JS, Leavitt A, Coderre TJ. Evidence that pregabalin reduces neuropathic pain by inhibiting the spinal release of glutamate. J Neurochem. 2010;113:552\u201361. https:\/\/doi.org\/10.1111\/j.1471-4159.2010.06625.x.","journal-title":"J Neurochem."},{"key":"1709_CR8","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.2147\/jpr.S203712","volume":"12","author":"M Akazawa","year":"2019","unstructured":"Akazawa M, Igarashi A, Ebata N, Murata T, Zeniya S, Haga Y, et al. A cost-effectiveness analysis of pregabalin for the treatment of patients with chronic cervical pain with a neuropathic component in Japan. J Pain Res. 2019;12:2785\u201397. https:\/\/doi.org\/10.2147\/jpr.S203712.","journal-title":"J Pain Res."},{"key":"1709_CR9","doi-asserted-by":"publisher","first-page":"505","DOI":"10.2147\/ceor.S89833","volume":"7","author":"A Igarashi","year":"2015","unstructured":"Igarashi A, Akazawa M, Murata T, Taguchi T, Sadosky A, Ebata N, et al. Cost-effectiveness analysis of pregabalin for treatment of chronic low back pain in patients with accompanying lower limb pain (neuropathic component) in Japan. Clinicoecon Outcomes Res. 2015;7:505\u201320. https:\/\/doi.org\/10.2147\/ceor.S89833.","journal-title":"Clinicoecon Outcomes Res."},{"key":"1709_CR10","doi-asserted-by":"crossref","unstructured":"Gianesello L, Pavoni V, Barboni E, Galeotti I, Nella A. Perioperative pregabalin for postoperative pain control and quality of life after major spinal surgery. J Neurosurg Anesthesiol. 2011. doi: 10.1097\/ANA.0b013e31823a885b [doi].","DOI":"10.1097\/ANA.0b013e31823a885b"},{"key":"1709_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-023600","volume":"9","author":"IJ Onakpoya","year":"2019","unstructured":"Onakpoya IJ, Thomas ET, Lee JJ, Goldacre B, Heneghan CJ. Benefits and harms of pregabalin in the management of neuropathic pain: a rapid review and meta-analysis of randomised clinical trials. BMJ Open. 2019;9:e023600. https:\/\/doi.org\/10.1136\/bmjopen-2018-023600.","journal-title":"BMJ Open."},{"key":"1709_CR12","doi-asserted-by":"crossref","unstructured":"Hindmarch I, Trick L, Ridout F. A double-blind, placebo- and positive-internal-controlled (alprazolam) investigation of the cognitive and psychomotor profile of pregabalin in healthy volunteers. Psychopharmacology (Berl). 2005;183:133-43. doi: 10.1007\/s00213-005-0172-7 [doi].","DOI":"10.1007\/s00213-005-0172-7"},{"key":"1709_CR13","doi-asserted-by":"crossref","unstructured":"Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain. 2004;110:628-38. doi: 10.1016\/j.pain.2004.05.001 [doi] S0304395904002465 [pii].","DOI":"10.1016\/j.pain.2004.05.001"},{"key":"1709_CR14","doi-asserted-by":"publisher","first-page":"307","DOI":"10.4103\/0970-9185.83672","volume":"27","author":"DK Baidya","year":"2011","unstructured":"Baidya DK, Agarwal A, Khanna P, Arora MK. Pregabalin in acute and chronic pain. J Anaesthesiol Clin Pharmacol. 2011;27:307\u201314. https:\/\/doi.org\/10.4103\/0970-9185.83672.","journal-title":"J Anaesthesiol Clin Pharmacol."},{"key":"1709_CR15","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s40265-019-01070-8","volume":"79","author":"ED Deeks","year":"2019","unstructured":"Deeks ED. Mirogabalin: first global approval. Drugs. 2019;79:463\u20138. https:\/\/doi.org\/10.1007\/s40265-019-01070-8.","journal-title":"Drugs."},{"key":"1709_CR16","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1124\/jpet.117.247551","volume":"365","author":"Y Domon","year":"2018","unstructured":"Domon Y, Arakawa N, Inoue T, Matsuda F, Takahashi M, Yamamura N, et al. Binding characteristics and analgesic effects of mirogabalin, a novel ligand for the \u03b12\u03b4 subunit of voltage-gated calcium channels. J Pharmacol Exp Ther. 2018;365:573\u201382. https:\/\/doi.org\/10.1124\/jpet.117.247551.","journal-title":"J Pharmacol Exp Ther."},{"key":"1709_CR17","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s00776-013-0529-4","volume":"19","author":"T Tetsunaga","year":"2014","unstructured":"Tetsunaga T, Tetsunaga T, Tanaka M, Sugimoto Y, Takigawa T, Ozaki T. Outcomes of pregabalin in lumbar-disease patients with depression. J Orthop Sci. 2014;19:229\u201334. https:\/\/doi.org\/10.1007\/s00776-013-0529-4.","journal-title":"J Orthop Sci."},{"key":"1709_CR18","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1212\/01.wnl.0000282763.29778.59","volume":"70","author":"RD Treede","year":"2008","unstructured":"Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. 2008;70:1630\u20135. https:\/\/doi.org\/10.1212\/01.wnl.0000282763.29778.59.","journal-title":"Neurology."},{"key":"1709_CR19","doi-asserted-by":"publisher","first-page":"254","DOI":"10.4184\/asj.2015.9.2.254","volume":"9","author":"Y Sakai","year":"2015","unstructured":"Sakai Y, Ito K, Hida T, Ito S, Harada A. Neuropathic pain in elderly patients with chronic low back pain and effects of pregabalin: a preliminary study. Asian Spine J. 2015;9:254\u201362. https:\/\/doi.org\/10.4184\/asj.2015.9.2.254.","journal-title":"Asian Spine J."},{"key":"1709_CR20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00776-013-0496-9","volume":"19","author":"T Yamashita","year":"2014","unstructured":"Yamashita T, Takahashi K, Yonenobu K, Kikuchi S. Prevalence of neuropathic pain in cases with chronic pain related to spinal disorders. J Orthop Sci. 2014;19:15\u201321. https:\/\/doi.org\/10.1007\/s00776-013-0496-9.","journal-title":"J Orthop Sci."},{"key":"1709_CR21","first-page":"1187","volume":"31","author":"S Ogawa","year":"2010","unstructured":"Ogawa S. Development of new screening questionnaire to identify neuropathic components in Japanese patients with chronic pain. Pain Clinic. 2010;31:1187\u201394.","journal-title":"Pain Clinic."},{"key":"1709_CR22","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/0304-3959(86)90228-9","volume":"27","author":"MP Jensen","year":"1986","unstructured":"Jensen MP, Karoly P, Braver S. The measurement of clinical pain intensity: a comparison of six methods. Pain. 1986;27:117\u201326 doi: 0304-3959(86)90228-9 [pii].","journal-title":"Pain."},{"key":"1709_CR23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1177\/2040622314552071","volume":"6","author":"S Javed","year":"2015","unstructured":"Javed S, Petropoulos IN, Alam U, Malik RA. Treatment of painful diabetic neuropathy. Ther Adv Chronic Dis. 2015;6:15\u201328. https:\/\/doi.org\/10.1177\/2040622314552071.","journal-title":"Ther Adv Chronic Dis."},{"key":"1709_CR24","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.2147\/jpr.S145999","volume":"11","author":"S Javed","year":"2018","unstructured":"Javed S, Alam U, Malik RA. Mirogabalin and emerging therapies for diabetic neuropathy. J Pain Res. 2018;11:1559\u201366. https:\/\/doi.org\/10.2147\/jpr.S145999.","journal-title":"J Pain Res."},{"key":"1709_CR25","unstructured":"The Committee for the Guidelines for the Pharmacologic Management of Neuropathic Pain of JSPC. Guidelines for the Pharmacologic Management of Neuropathic Pain Second Edition: Publication Department, Shinko Trading Co. Ltd.; 2016."},{"key":"1709_CR26","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1016\/j.pain.2013.06.004","volume":"154","author":"RH Dworkin","year":"2013","unstructured":"Dworkin RH, O'Connor AB, Kent J, Mackey SC, Raja SN, Stacey BR, et al. Interventional management of neuropathic pain: NeuPSIG recommendations. Pain. 2013;154:2249\u201361. https:\/\/doi.org\/10.1016\/j.pain.2013.06.004.","journal-title":"Pain."},{"key":"1709_CR27","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1212\/WNL.0b013e3182166ebe","volume":"76","author":"V Bril","year":"2011","unstructured":"Bril V, England J, Franklin GM, Backonja M, Cohen J, Del Toro D, et al. Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology. 2011;76:1758\u201365. https:\/\/doi.org\/10.1212\/WNL.0b013e3182166ebe.","journal-title":"Neurology."},{"key":"1709_CR28","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1111\/j.1468-1331.2010.02999.x","volume":"17","author":"N Attal","year":"2010","unstructured":"Attal N, Cruccu G, Baron R, Haanpaa M, Hansson P, Jensen TS, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17:1113\u2013e88. https:\/\/doi.org\/10.1111\/j.1468-1331.2010.02999.x.","journal-title":"Eur J Neurol."},{"key":"1709_CR29","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1155\/2014\/754693","volume":"19","author":"D Moulin","year":"2014","unstructured":"Moulin D, Boulanger A, Clark AJ, Clarke H, Dao T, Finley GA, et al. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res Manag. 2014;19:328\u201335. https:\/\/doi.org\/10.1155\/2014\/754693.","journal-title":"Pain Res Manag."},{"key":"1709_CR30","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1111\/jdi.13013","volume":"10","author":"M Baba","year":"2019","unstructured":"Baba M, Matsui N, Kuroha M, Wasaki Y, Ohwada S. Mirogabalin for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo-controlled phase III study in Asian patients. J Diabetes Investig. 2019;10:1299\u2013306. https:\/\/doi.org\/10.1111\/jdi.13013.","journal-title":"J Diabetes Investig."},{"key":"1709_CR31","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1097\/j.pain.0000000000001501","volume":"160","author":"J Kato","year":"2019","unstructured":"Kato J, Matsui N, Kakehi Y, Murayama E, Ohwada S, Sugihara M. Mirogabalin for the management of postherpetic neuralgia: a randomized, double-blind, placebo-controlled phase 3 study in Asian patients. Pain. 2019;160:1175\u201385. https:\/\/doi.org\/10.1097\/j.pain.0000000000001501.","journal-title":"Pain."},{"key":"1709_CR32","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s00210-019-01628-z","volume":"392","author":"K Saeki","year":"2019","unstructured":"Saeki K, Yasuda SI, Kato M, Kano M, Domon Y, Arakawa N, et al. Analgesic effects of mirogabalin, a novel ligand for \u03b12\u03b4 subunit of voltage-gated calcium channels, in experimental animal models of fibromyalgia. Naunyn Schmiedebergs Arch Pharmacol. 2019;392:723\u20138. https:\/\/doi.org\/10.1007\/s00210-019-01628-z.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol."},{"key":"1709_CR33","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.pain.2010.12.014","volume":"152","author":"A Boroujerdi","year":"2011","unstructured":"Boroujerdi A, Zeng J, Sharp K, Kim D, Steward O, Luo ZD. Calcium channel alpha-2-delta-1 protein upregulation in dorsal spinal cord mediates spinal cord injury-induced neuropathic pain states. Pain. 2011;152:649\u201355. https:\/\/doi.org\/10.1016\/j.pain.2010.12.014.","journal-title":"Pain."},{"key":"1709_CR34","doi-asserted-by":"publisher","first-page":"8494","DOI":"10.1523\/jneurosci.2982-04.2004","volume":"24","author":"CY Li","year":"2004","unstructured":"Li CY, Song YH, Higuera ES, Luo ZD. Spinal dorsal horn calcium channel \u03b12\u03b4-1 subunit upregulation contributes to peripheral nerve injury-induced tactile allodynia. J Neurosci. 2004;24:8494\u20139. https:\/\/doi.org\/10.1523\/jneurosci.2982-04.2004.","journal-title":"J Neurosci."},{"key":"1709_CR35","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.pain.2006.04.022","volume":"125","author":"CY Li","year":"2006","unstructured":"Li CY, Zhang XL, Matthews EA, Li KW, Kurwa A, Boroujerdi A, et al. Calcium channel \u03b12\u03b4 1 subunit mediates spinal hyperexcitability in pain modulation. Pain. 2006;125:20\u201334. https:\/\/doi.org\/10.1016\/j.pain.2006.04.022.","journal-title":"Pain."},{"key":"1709_CR36","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1136\/jmedgenet-2012-101223","volume":"50","author":"S Edvardson","year":"2013","unstructured":"Edvardson S, Oz S, Abulhijaa FA, Taher FB, Shaag A, Zenvirt S, et al. Early infantile epileptic encephalopathy associated with a high voltage gated calcium channelopathy. J Med Genet. 2013;50:118\u201323. https:\/\/doi.org\/10.1136\/jmedgenet-2012-101223.","journal-title":"J Med Genet."},{"key":"1709_CR37","doi-asserted-by":"publisher","first-page":"17537","DOI":"10.1073\/pnas.0409066103","volume":"103","author":"MJ Field","year":"2006","unstructured":"Field MJ, Cox PJ, Stott E, Melrose H, Offord J, Su TZ, et al. Identification of the \u03b1 2-\u03b4-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. Proc Natl Acad Sci U S A. 2006;103:17537\u201342. https:\/\/doi.org\/10.1073\/pnas.0409066103.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"1709_CR38","doi-asserted-by":"publisher","first-page":"6095","DOI":"10.1523\/JNEUROSCI.21-16-06095.2001","volume":"21","author":"J Barclay","year":"2001","unstructured":"Barclay J, Balaguero N, Mione M, Ackerman SL, Letts VA, Brodbeck J, et al. Ducky mouse phenotype of epilepsy and ataxia is associated with mutations in the Cacna2d2 gene and decreased calcium channel current in cerebellar Purkinje cells. J Neurosci. 2001;21:6095\u2013104.","journal-title":"J Neurosci."},{"key":"1709_CR39","doi-asserted-by":"publisher","first-page":"3253","DOI":"10.2337\/dc14-1044","volume":"37","author":"A Vinik","year":"2014","unstructured":"Vinik A, Rosenstock J, Sharma U, Feins K, Hsu C, Merante D. Efficacy and safety of mirogabalin (DS-5565) for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo- and active comparator-controlled, adaptive proof-of-concept phase 2 study. Diabetes Care. 2014;37:3253\u201361. https:\/\/doi.org\/10.2337\/dc14-1044.","journal-title":"Diabetes Care."},{"key":"1709_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0193987","volume":"13","author":"T Nikaido","year":"2018","unstructured":"Nikaido T, Sumitani M, Sekiguchi M, Konno S. The Spine painDETECT questionnaire: development and validation of a screening tool for neuropathic pain caused by spinal disorders. PLoS One. 2018;13:e0193987. https:\/\/doi.org\/10.1371\/journal.pone.0193987.","journal-title":"PLoS One."}],"container-title":["Journal of Orthopaedic Surgery and Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13018-020-01709-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13018-020-01709-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13018-020-01709-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T19:23:05Z","timestamp":1621970585000},"score":1,"resource":{"primary":{"URL":"https:\/\/josr-online.biomedcentral.com\/articles\/10.1186\/s13018-020-01709-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,26]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1709"],"URL":"https:\/\/doi.org\/10.1186\/s13018-020-01709-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.22707\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.22707\/v1","asserted-by":"object"}]},"ISSN":["1749-799X"],"issn-type":[{"value":"1749-799X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,26]]},"assertion":[{"value":"1 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Kurashiki Municipal Hospital ethics committee approved this research.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"191"}}